Sandoz unveils biosimilar Pyzchiva across Europe to treat chronic inflammatory diseases Ruchika Sharma28 July 2024 10:30 AM ISTBasel: Sandoz has announced the launch of Pyzchiva (ustekinumab) across Europe. Pyzchiva, developed and registered by Samsung Bioepis, a ustekinumab...
Sandoz confirms European Commission nod of Pyzchiva Ruchika Sharma23 April 2024 11:54 AM ISTBasel: Sandoz has announced that the European Commission (EC) has granted marketing authorization for Pyzchiva (biosimilar ustekinumab) developed...
Sandoz gets exclusive rights to commercialize biosimilar SB17 ustekinumab in US, Canada, EEA, Switzerland and UK Ruchika Sharma11 Sept 2023 1:30 PM ISTThe reference medicine Stelara (ustekinumab) is a monoclonal antibody medication to interleukin (IL)-12/23 for the treatment of autoimmune disorders...
Biogen, Samsung Bioepis launch USFDA approved BYOOVIZ in US Ruchika Sharma5 Jun 2022 9:00 AM ISTBYOOVIZ is the first biosimilar launch in the U.S. under the Biogen and Samsung Bioepis' partnership.
